1. Home
  2. SCS vs LQDA Comparison

SCS vs LQDA Comparison

Compare SCS & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCS
  • LQDA
  • Stock Information
  • Founded
  • SCS 1912
  • LQDA 2004
  • Country
  • SCS United States
  • LQDA United States
  • Employees
  • SCS N/A
  • LQDA N/A
  • Industry
  • SCS Office Equipment/Supplies/Services
  • LQDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • SCS Consumer Discretionary
  • LQDA Health Care
  • Exchange
  • SCS Nasdaq
  • LQDA Nasdaq
  • Market Cap
  • SCS 1.2B
  • LQDA 1.3B
  • IPO Year
  • SCS 1998
  • LQDA 2018
  • Fundamental
  • Price
  • SCS $10.22
  • LQDA $13.17
  • Analyst Decision
  • SCS Strong Buy
  • LQDA Strong Buy
  • Analyst Count
  • SCS 2
  • LQDA 9
  • Target Price
  • SCS $17.00
  • LQDA $27.67
  • AVG Volume (30 Days)
  • SCS 711.5K
  • LQDA 3.0M
  • Earning Date
  • SCS 06-25-2025
  • LQDA 08-06-2025
  • Dividend Yield
  • SCS 3.93%
  • LQDA N/A
  • EPS Growth
  • SCS 50.00
  • LQDA N/A
  • EPS
  • SCS 1.02
  • LQDA N/A
  • Revenue
  • SCS $3,166,000,000.00
  • LQDA $14,144,000.00
  • Revenue This Year
  • SCS $4.20
  • LQDA $185.38
  • Revenue Next Year
  • SCS $4.09
  • LQDA $350.95
  • P/E Ratio
  • SCS $9.97
  • LQDA N/A
  • Revenue Growth
  • SCS 0.20
  • LQDA N/A
  • 52 Week Low
  • SCS $9.32
  • LQDA $8.26
  • 52 Week High
  • SCS $14.74
  • LQDA $19.41
  • Technical
  • Relative Strength Index (RSI)
  • SCS 46.85
  • LQDA 36.80
  • Support Level
  • SCS $10.12
  • LQDA $13.60
  • Resistance Level
  • SCS $10.89
  • LQDA $14.63
  • Average True Range (ATR)
  • SCS 0.26
  • LQDA 0.96
  • MACD
  • SCS -0.03
  • LQDA -0.40
  • Stochastic Oscillator
  • SCS 13.46
  • LQDA 0.46

About SCS Steelcase Inc.

Steelcase Inc is a furniture company based in the United States. Its brands, such as Steelcase, AMQ, Coalesse, Designtex, and others, offer a portfolio of furniture and architectural products and services designed to help customers create workplaces. It markets its products and services to businesses and organizations predominantly through a network of dealers and also sells to consumers in markets around the world through web-based and retail distribution channels. The company's reportable segments include the Americas, which generates key revenue, and the International segment.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: